Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Apr 19;5(3):603-606.
doi: 10.1002/jha2.874. eCollection 2024 Jun.

Severe anaphylaxis after chimeric antigen receptor T-cell injection: a case report

Sarah Morin  1   2 , Filippo Boroli  3 , Sophie Vandenberghe-Durr  4 , Daniele Allali  4 , Stavroula Masouridi-Levrat  1 , Yves Chalandon  1   2 , Federico Simonetta  1   2
Affiliations
Case Reports

Severe anaphylaxis after chimeric antigen receptor T-cell injection: a case report

Sarah Morin et al. EJHaem. .

Abstract

Anaphylactic reactions at the time of chimeric antigen receptor T (CAR-T) cell infusion are adverse events that have not been reported in pivotal clinical trials or in real-world series. We report the case of patient with severe anaphylaxis with cardiac arrest after tisagenlecleucel injection for Diffuse Large B cell Lymphoma, who recovered after resuscitation and intensive care treatment; we also conducted a Food and Drug Administration Adverse Event Reporting System database analysis and found several cases of severe anaphlyaxis after CAR-T cell injection. Although not reported in pivotal CAR-T cell studies, anaphylaxis can occur after CAR-T cell injection, highlighting the need to include anaphylaxis as a possible side effect in future studies.

Keywords: CAR‐T cells; anaphylaxis; cardiac arrest; tisagenlecleucel.

PubMed Disclaimer

Conflict of interest statement

Yves Chalandon: advisory board from MSD; BMS, Novartis, Roche, Jazz, Gilead, Amgen, Incyte, Astra Zeneca, and Servier. Travel expenses to scientific meetings supported by MSD, Roche Gilead Amgen Incyte Abbvie, Janssen, Astra‐Zeneca, Jazz, and Sanofi. Federico Simonetta: institutional consulting fees from BMS/Celgene, Incyte, and Kite/Gilead; speaker fees from Kite/Gilead, Incyte; travel support from Kite/Gilead, Novartis, AstraZeneca, Neovii, and Janssen; research funding from Kite/Gilead, Novartis, and BMS/Celgene.

References

    1. Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT Consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625–638. - PubMed
    1. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B‐cell lymphoblastic leukemia. New Engl J Med. 2018;378(5):439–448. - PMC - PubMed
    1. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B‐cell lymphoma. New Engl J Med. 2019;380(1):45–56. - PubMed
    1. Fowler NH, Dickinson M, Dreyling M, Martinez‐Lopez J, Kolstad A, Butler J, et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med. 2022;28(2):325–332. - PubMed
    1. Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, et al. Axicabtagene ciloleucel as second‐line therapy for large B‐cell lymphoma. New Engl J Med. 2022;386(7):640–654. - PubMed

Publication types